Skip Nav Destination
Close Modal
Update search
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
NARROW
Format
Subjects
Journal
Article Type
Issue Section
Date
Availability
1-6 of 6
Keywords: Toxicity
Close
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Sort by
Journal Articles
Subject Area:
Oncology
Antonio Piras, Luca Boldrini, Sebastiano Menna, Antonella Sanfratello, Andrea D’Aviero, Davide Cusumano, Luciana Di Cristina, Marco Messina, Massimiliano Spada, Tommaso Angileri, Antonino Daidone
Journal:
Oncology Research and Treatment
Oncol Res Treat (2022) 45 (7-8): 408–414.
Published Online: 16 February 2022
...). The benefit in terms of clinical control and toxicity for stereotactic radiotherapy (SRT) has been investigated for patients with low load of BrM. Aim: The aim of this single-institution experience was to investigate the best dose schedule for five-fraction SRT (FFSRT). Methods: A retrospective analysis...
Journal Articles
Journal:
Oncology Research and Treatment
Oncol Res Treat (2022) 45 (1-2): 12–17.
Published Online: 18 November 2021
... rapid tumor response are generally suitable for MCT. However, MCT may also be promising in patients with triple-negative and HER2-positive tumors without aggressive disease who prefer a lower toxicity profile compared to CCT. The most commonly used agents are cyclophosphamide (CTX), methotrexate (MTX...
Journal Articles
Subject Area:
Oncology
Fabienne Schochter, Brigitte Rack, Marie Tzschaschel, Arkadius Polasik, Ulrich Andergassen, Elisabeth Trapp, Marianna Alunni-Fabbroni, Andreas Schneeweiss, Volkmar Müller, Klaus Pantel, Jörg Gade, Ralf Lorenz, Mahdi Rezai, Hans Tesch, Ulrike Soeling, Tanja Fehm, Sven Mahner, Christian Schindlbeck, Werner Lichtenegger, Matthias W. Beckmann, Peter A. Fasching, Wolfgang Janni, Thomas W.P. Friedl, on behalf of the SUCCESS Study Group
Journal:
Oncology Research and Treatment
Oncol Res Treat (2018) 41 (3): 93–98.
Published Online: 27 February 2018
... responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. 2018 Early breast cancer Endocrine therapy Exemestane Tamoxifen Circulating tumor cells CTC clearance rate Safety Toxicity For many...
Journal Articles
Subject Area:
Oncology
Journal:
Oncology Research and Treatment
Oncol Res Treat (2017) 40 (12): 784–788.
Published Online: 29 November 2017
... Community-based practices Survival Outpatient treatment Toxicity Pancreatic ductal adenocarcinoma is a disease associated with a poor prognosis despite advances in cancer therapy and improvements in cancer-related mortality. It is the 6th most common cause of cancer-related mortality in Europe...
Journal Articles
Subject Area:
Oncology
Catalina M. Acevedo-Henao, Jose L. Lopez Guerra, Raul Matute, Fernando Puebla, Moises Russo, Eleonor Rivin, Alberto Sanchez-Reyes, M. José Ortiz, Ignacio Azinovic
Journal:
Oncology Research and Treatment
Oncol Res Treat (2014) 37 (6): 324–330.
Published Online: 12 May 2014
... factors for genitourinary (GU) and gastrointestinal (GI) toxicity were assessed. Results: The median age was 68 years (range 51-87 years). The median follow-up was 37 months (range 3-74 months). The rates of acute grade 2 GI and GU toxicities were 10 and 13%, respectively. Only 1 patient experienced acute...
Journal Articles
Subject Area:
Oncology
Journal:
Oncology Research and Treatment
Oncol Res Treat (2014) 37 (5): 262–265.
Published Online: 14 April 2014
... of the limited experience and potential side effects known for other EGFR TKIs, a decision for treatment outside a clinical trial has to be made very carefully, balancing the risk and benefit on an individual patient basis. Lung cancer EGFR Afatinib Radiotherapy Toxicity 16 01 2014 21 03...